Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L29 pseudogene 14 (RPL29P14)
- Target
- RPL29P14
- Molecular classification
- Pseudogene
01
Overview
Ribosomal protein L29 pseudogene 14 (RPL29P14) is a processed pseudogene in the human genome, named for its homology to the functional ribosomal protein gene RPL29. Pseudogenes such as RPL29P14 are similar in sequence to protein-coding genes but usually do not encode functional proteins due to mutations, truncations, or lack of regulatory elements needed for expression. The RPL29 gene encodes a structural component of the large (60S) ribosomal subunit, essential for protein synthesis; however, RPL29P14 lacks this function and is not known to have any direct biological or disease role. Pseudogenes can sometimes serve as raw material for genetic evolution or regulatory elements, but there is no evidence RPL29P14 has such roles in humans to date.
- Other names
- RPL29P14
02
Mechanism of action
None. There are no drugs that act on this pseudogene; mechanisms of action are not applicable.
03
Biological functions
None. As a pseudogene, RPL29P14 does not encode a functional protein and thus has no direct biological function. Pseudogenes are segments of DNA that resemble functional genes but typically lack the ability to be translated into proteins.
04
Disease associations
None. There are no reported roles for RPL29P14 in disease, and it does not participate in known disease pathways. This is consistent with its classification as a pseudogene.Mutations in related protein-coding ribosomal protein genes, such as RPL29, are linked to certain diseases, but this does not apply to RPL29P14.
05
Safety considerations
None. There are no notable safety or therapeutic challenges associated with this pseudogene, as it is not a drug target or expressed product.
06
Interacting drugs
None. There are no drugs that interact with RPL29P14, as it is not expressed as a protein and is not used as a therapeutic or diagnostic target.
07
Biomarkers
None. No current use in patient selection or efficacy monitoring.
Beyond the preview
Go deeper on Ribosomal protein L29 pseudogene 14 (RPL29P14).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L29 pseudogene 14 (RPL29P14).